Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.

Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, Stanczyk F, DeMichele A.

Breast Cancer Res. 2011 Jan 20;13(1):R8. doi: 10.1186/bcr2813.

2.

Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias.

Galantino ML, Desai K, Greene L, Demichele A, Stricker CT, Mao JJ.

Integr Cancer Ther. 2012 Dec;11(4):313-20. doi: 10.1177/1534735411413270. Epub 2011 Jul 6.

PMID:
21733988
3.

Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.

Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A.

Cancer. 2009 Aug 15;115(16):3631-9. doi: 10.1002/cncr.24419.

4.

Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.

Galantino ML, Callens ML, Cardena GJ, Piela NL, Mao JJ.

Altern Ther Health Med. 2013 Nov-Dec;19(6):38-44.

PMID:
24254037
5.

A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias.

Galantino ML, Greene L, Archetto B, Baumgartner M, Hassall P, Murphy JK, Umstetter J, Desai K.

Explore (NY). 2012 Jan-Feb;8(1):40-7. doi: 10.1016/j.explore.2011.10.002.

PMID:
22225932
6.

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.

Napoli N, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G, Giri T, Mueller C, Kulkarny V, Qualls C, Ellis M, Armamento-Villareal R.

Bone. 2013 Aug;55(2):309-14. doi: 10.1016/j.bone.2013.04.021. Epub 2013 May 1.

7.

Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.

Brown JC, Mao JJ, Stricker C, Hwang WT, Tan KS, Schmitz KH.

Breast J. 2014 Jan-Feb;20(1):22-8. doi: 10.1111/tbj.12202. Epub 2013 Oct 25.

8.

Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors.

Mao JJ, Bruner DW, Stricker C, Farrar JT, Xie SX, Bowman MA, Pucci D, Han X, DeMichele A.

Integr Cancer Ther. 2009 Jun;8(2):123-9. doi: 10.1177/1534735409332903.

9.

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.

Napoli N, Rastelli A, Ma C, Colleluori G, Vattikuti S, Armamento-Villareal R.

Pharmacogenet Genomics. 2015 Aug;25(8):377-81. doi: 10.1097/FPC.0000000000000146.

10.

Aromatase inhibitor-associated arthralgia syndrome.

Burstein HJ.

Breast. 2007 Jun;16(3):223-34. Epub 2007 Mar 21. Review.

PMID:
17368903
11.

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.

Ferraldeschi R, Arnedos M, Hadfield KD, A'Hern R, Drury S, Wardley A, Howell A, Evans DG, Roberts SA, Smith I, Newman WG, Dowsett M.

Breast Cancer Res Treat. 2012 Jun;133(3):1191-8. doi: 10.1007/s10549-012-2010-z. Epub 2012 Mar 15.

PMID:
22418701
12.

Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.

Nyrop KA, Muss HB, Hackney B, Cleveland R, Altpeter M, Callahan LF.

J Geriatr Oncol. 2014 Apr;5(2):148-55. doi: 10.1016/j.jgo.2013.12.002. Epub 2013 Dec 28.

PMID:
24495696
13.

Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.

Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF.

Cancer. 2013 Jul 1;119(13):2375-82. doi: 10.1002/cncr.28016. Epub 2013 Apr 10.

14.

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.

Simonsson M, Veerla S, Markkula A, Rose C, Ingvar C, Jernström H.

BMC Cancer. 2016 Mar 31;16:256. doi: 10.1186/s12885-016-2284-3.

15.

Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.

Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, DeMichele A, Mao JJ.

BMC Cancer. 2013 Sep 3;13:401. doi: 10.1186/1471-2407-13-401.

16.

Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.

Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P, Bouhassira D, Perrot S.

J Pain. 2014 Mar;15(3):293-303. doi: 10.1016/j.jpain.2013.11.004. Epub 2013 Dec 21.

PMID:
24365325
17.

Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.

Lintermans A, Van Asten K, Jongen L, Van Brussel T, Laenen A, Verhaeghe J, Vanderschueren D, Lambrechts D, Neven P.

Eur J Cancer. 2016 Mar;56:31-6. doi: 10.1016/j.ejca.2015.12.013. Epub 2016 Jan 19.

PMID:
26798969
18.

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.

Fontein DB, Houtsma D, Nortier JW, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, Putter H, Seynaeve C, Gelderblom H, van de Velde CJ, Guchelaar HJ.

Breast Cancer Res Treat. 2014 Apr;144(3):599-606. doi: 10.1007/s10549-014-2873-2. Epub 2014 Mar 4.

PMID:
24590773
19.

Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors.

Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J.

J Clin Oncol. 2015 Apr 1;33(10):1104-11. doi: 10.1200/JCO.2014.57.1547. Epub 2014 Dec 1.

20.

Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.

Borrie AE, Kim RB.

Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):149-156. doi: 10.1080/17425255.2017.1234605. Epub 2016 Sep 20. Review.

PMID:
27635473

Supplemental Content

Support Center